CNS Pharmaceuticals Appoints New CEO to Advance Brain Cancer Treatments

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for primary and metastatic cancers of the brain and central nervous system, has announced a significant leadership transition. Effective January 1, 2026, John Climaco will step down as chief executive officer, with Rami Levin, MBA, appointed as the new president and chief executive officer. Levin brings nearly three decades of global leadership experience in oncology, neurology, and rare diseases, with a proven track record of advancing late-stage clinical programs, scaling organizations, and leading strategic turnarounds. This leadership change positions CNS Pharmaceuticals to advance its pipeline and enter its next phase of development, potentially accelerating progress in critical cancer treatments.

The company's promising drug candidate, TPI 287, represents a significant advancement in treating central nervous system tumors. As an abeotaxane, TPI 287 stabilizes microtubules and inhibits cell division, leading to apoptosis and cell death. Initial clinical efficacy data suggest this drug has the potential to cross the blood-brain barrier—a major challenge in treating brain cancers—and effectively target CNS tumors. TPI 287 has been tested in over 350 patients across various clinical trials, both as a monotherapy and in combination with bevacizumab, for conditions including recurrent glioblastoma, recurrent neuroblastoma, medulloblastoma, advanced malignancies, pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date, the drug appears to maintain both an excellent safety profile and high tolerability among patients, making it a promising candidate for further development.

This news release was distributed through MissionIR, a specialized communications platform within the Dynamic Brand Portfolio at IBN that focuses on enhancing the visibility of companies within the investment community. MissionIR provides access to wire solutions through InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release services, social media distribution to millions of followers, and tailored corporate communications solutions. For investors and stakeholders seeking more information, the latest updates relating to CNSP are available in the company's newsroom, and the full press release can be accessed through the provided link. This leadership transition at CNS Pharmaceuticals represents a strategic move that could significantly impact the development timeline of potentially life-saving treatments for some of the most challenging cancers affecting the brain and central nervous system.